Please enable JS

Investors

Press Releases

 
Press Releases
  Date Title View
Mar 17, 2005
CAMBRIDGE, Mass., March 17, 2005 /PRNewswire-FirstCall via COMTEX/ -- Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA), a biotechnology company developing drugs based on its proprietary sugar sequencing technology, announced today that Marsha Fanucci has been elected to Momenta's Board of Directors, replacing John Zabriskie, Ph.D. "I a...
Mar 10, 2005
CAMBRIDGE, Mass., March 10, 2005 /PRNewswire-FirstCall via COMTEX/ -- Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA), a biotechnology company developing drugs based on its proprietary sugar sequencing technology, announced today that Alan Crane, Chairman and Chief Executive Officer, will present at the SG Cowen 25th Annual Health Care Conferen...
Feb 10, 2005
CAMBRIDGE, Mass., Feb. 10 /PRNewswire-FirstCall/ -- Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA), a biotechnology company developing drugs based on its proprietary sugar sequencing technology, today announced its financial results for the fourth quarter and fiscal year ended December 31, 2004. For the fourth quarter 2004, the...
Feb 3, 2005
CAMBRIDGE, Mass., Feb 03, 2005 /PRNewswire-FirstCall via COMTEX/ -- Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA), a biotechnology company developing drugs based on its proprietary sugar sequencing technology, will report financial results for the fourth quarter 2004 on Thursday, February 10, 2005 before the opening of the U.S. financial mark...
Jan 13, 2005
CAMBRIDGE, Mass., Jan 13, 2005 /PRNewswire-FirstCall via COMTEX/ -- Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA), a biotechnology company developing drugs based on sugar sequencing technology, today announced its goals relating to the application of its proprietary technology to therapeutic protein drugs containing sugars. Momenta's goals f...
Jan 6, 2005
CAMBRIDGE, Mass., Jan. 6 /PRNewswire-FirstCall/ -- Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA), a biotechnology company developing drugs based on sugar sequencing technology, announced today that its Chairman and Chief Executive Officer, Alan Crane, will present at the JP Morgan Twenty- Third Annual Healthcare Conference on Thursday, Ja...
Nov 16, 2004
CAMBRIDGE, Mass., Nov. 16 /PRNewswire-FirstCall/ -- Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA), a biotechnology company developing drugs based on sugar sequencing technology, today announced the appointment of John E. Bishop, Ph.D. as Vice President, Pharmaceutical Sciences and Manufacturing and Michael A. Lawless as Senior Director, I...
Nov 12, 2004
CAMBRIDGE, Mass., Nov. 12 /PRNewswire-FirstCall/ -- Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA), a biotechnology company developing drugs based on sugar sequencing technology, announced today that its Chairman and Chief Executive Officer, Alan Crane, will present at the SG Cowen 5th Annual Global Health Care Conference on Wednesday, Nov...
Nov 5, 2004
CAMBRIDGE, Mass., Nov. 5 /PRNewswire-FirstCall/ -- Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA), a biotechnology company developing drugs based on sugar sequencing technology, today announced its financial results for the quarter ended September 30, 2004 and reported on recent corporate developments. For the quarter ended Sep...
Oct 29, 2004
CAMBRIDGE, Mass., Oct. 29 /PRNewswire-FirstCall/ -- Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA), a biotechnology company developing drugs based on sugar sequencing technology, announced today that its Chairman and Chief Executive Officer, Alan Crane, will present at the CIBC World Markets Fifteenth Annual Healthcare Conference on Monday...
FirstPrevious
...
40
NextLast
= add release to Briefcase